InvestorsHub Logo
Followers 183
Posts 37293
Boards Moderated 3
Alias Born 09/24/2000

Re: Monksdream post# 26

Tuesday, 09/26/2023 2:09:55 PM

Tuesday, September 26, 2023 2:09:55 PM

Post# of 36
Item 8.01

Other Events.

On August 16, 2023, Elevation Oncology, Inc. (the “Company”) announced that the first patient has been dosed in the Phase 1 clinical trial evaluating EO-3021 in patients with advanced unresectable or metastatic solid tumors likely to express Claudin 18.2 including gastric, gastroesophageal junction, pancreatic or esophageal cancers. The Company expects to report preliminary safety and anti-tumor data from its Phase 1 study during the first half of 2025.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELEV News